MedPath

Tagged News

BioDuro and Atombeat Launch AI-Powered Platform to Accelerate Peptide Drug Discovery

AI
  • BioDuro and Atombeat have announced a strategic partnership to develop an AI-driven platform that accelerates peptide drug discovery from molecular design to preclinical candidates.
  • The collaboration combines Atombeat's AI modeling technologies, capable of exploring over one trillion peptide compounds in silico, with BioDuro's expertise in peptide chemistry and high-throughput synthesis.
  • The integrated platform enables rapid screening of peptide candidates based on key traits like membrane permeability before lab testing, followed by BioDuro's ability to produce hundreds of high-purity peptides within one week.
  • This end-to-end workflow aims to deliver faster timelines and better cost-effectiveness for developing next-generation peptide therapeutics across broad therapeutic areas.

Major Pharma Companies Establish Innovation Hubs in Hyderabad to Accelerate Drug Development

AI
  • Agilent Technologies opened a new Biopharma Experience Center in Hyderabad, offering end-to-end solutions across chromatography, mass spectrometry, cell analysis, and lab informatics to accelerate drug development.
  • Eli Lilly inaugurated a 2.20 lakh square foot technology and innovation hub in Hyderabad, planning to expand from 100 to 1,500 professionals focused on AI, automation, and software engineering.
  • Both investments reinforce Hyderabad's position as a global hub for life sciences innovation, with the city hosting eight of the top ten global pharma companies and over 230 US FDA-approved manufacturing facilities.
  • The facilities are designed to leverage India's talent pool in artificial intelligence and data sciences while supporting global drug development pipelines for major health challenges including diabetes, obesity, Alzheimer's disease, and cancer.

Nota AI Receives Fast-Track KOSDAQ Approval for AI Optimization Technology IPO

AI
  • Nota AI secured preliminary KOSDAQ listing approval in just two months, positioning to become the first AI optimization company on the Korean exchange amid challenging market conditions.
  • The company's proprietary NetsPresso® platform has established partnerships with global semiconductor leaders including NVIDIA, Samsung Electronics, and Qualcomm for AI model optimization.
  • Nota AI achieved nearly tenfold revenue growth over five years and projects 72% year-over-year growth in 2025, with expansion into industrial safety, surveillance, and transportation systems.
  • The company became the first Korean firm to deliver generative AI solutions to a Middle East government agency through its Dubai RTA contract in April 2025.

Relief Therapeutics to Merge with NeuroX in CHF 1 Billion Deal Creating AI-Driven Neurotherapeutics Platform

AIPrecision Medicine
  • Relief Therapeutics announced a binding agreement to merge with NeuroX Group, which recently acquired MindMaze's digital neurotherapeutics assets, in a transaction valued at CHF 1 billion for NeuroX and CHF 100 million for Relief.
  • The combined entity will create an AI-powered therapeutics platform integrating software-based neurorehabilitation with pharmacological treatments for neurological conditions including stroke, Parkinson's disease, and dementia.
  • Relief shareholders will own approximately 9% of the merged company, which will continue trading on the SIX Swiss Exchange with closing expected in Q4 2025.
  • NeuroX brings a clinically validated portfolio of digital neurotherapeutics backed by over USD 350 million in investment and partnerships with leading pharmaceutical companies across multiple clinical trials.

Brain-Inspired Supercomputer Deployed at Leipzig University to Accelerate AI-Driven Drug Discovery

AIDrug Discovery
  • SpiNNcloud has delivered the world's largest brain-inspired supercomputer system to Leipzig University in Germany, featuring 650,000 cores specifically designed for small-molecule drug discovery research.
  • The system can simulate up to 10.5 billion neurons and screen 20 billion molecules in less than an hour, representing a two-orders-of-magnitude speed improvement over traditional 1000 CPU core systems.
  • The supercomputer operates with 18 times greater energy efficiency than current GPU-based systems, utilizing a unique architecture with 10 million ARM-based processors and specialized neural network accelerators.
  • Leipzig University plans to use the system primarily for protein folding simulations to advance personalized medicine by identifying molecular interactions with patient profiles.

Absci Raises $50 Million to Advance AI-Driven Drug Discovery Platform and Internal Pipeline

AIDrug Discovery
  • Absci Corporation completed a $50 million public offering of 16.67 million shares at $3.00 per share to fund its AI-powered drug discovery programs and internal pipeline development.
  • The company's cash reserves increased to $134 million as of March 2025, extending its operational runway through 2027 while advancing preclinical candidates ABS-101 and ABS-201.
  • Absci's Integrated Drug Creation platform combines generative AI with synthetic biology and has secured partnerships with pharmaceutical giants including Merck and Moderna.
  • The AI-driven biologics market is projected to grow from $13.9 billion in 2024 to over $30 billion by 2030, positioning Absci in a rapidly expanding sector.

CDx Diagnostics Receives FDA Breakthrough Device Designation for AI-Powered WATS3D Esophageal Cancer Diagnostic System

AI
  • CDx Diagnostics received FDA Breakthrough Device Designation for its WATS3D diagnostic system, a first-of-a-kind AI-powered digital pathology platform for diagnosing Barrett's esophagus and early neoplastic changes.
  • The system demonstrated superior effectiveness compared to the Seattle biopsy protocol in large multi-center studies involving over 23,000 patients for detecting dysplasia and esophageal cancer.
  • The WATS3D Test leverages artificial intelligence and 3D digital imaging to identify precancerous and cancerous cells, potentially detecting early-stage disease missed by conventional biopsies.
  • The diagnostic platform has analyzed over 400,000 patient samples and aims to improve early detection of patients at risk for esophageal cancer progression.

Flatiron Health Triples Global Oncology Research Network, Expanding Real-World Data Access Across Three Countries

AIPrecision Medicine
  • Flatiron Health's international oncology research network has tripled in size over the past year, now encompassing more than 30 partnerships across the UK, Germany, and Japan.
  • The expansion brings Flatiron's total patient database above 5 million records, with new partnerships including major academic medical centers and national cancer centers in each country.
  • The company established Flatiron FORUM, a global consortium addressing data transportability challenges to support multinational cancer research and regulatory decisions.
  • Seven research studies using multinational real-world data have been completed within the past two years, demonstrating the platform's capability for cross-country cohort analyses.

AI-Guided Drug LP-284 Achieves Complete Response in Treatment-Resistant Lymphoma Patient

AIOrphan Drug
  • Lantern Pharma's LP-284 achieved complete metabolic response in a heavily pretreated diffuse large B-cell lymphoma patient after just two treatment cycles.
  • The 41-year-old patient had previously failed three aggressive treatment regimens including CAR-T therapy and bispecific antibody therapy over 18 months.
  • LP-284 was developed using Lantern's RADR® AI platform in under three years at approximately $3 million, demonstrating computational efficiency in drug development.
  • The synthetic lethal therapy targets cancer cells with DNA damage repair deficiencies while preserving healthy tissue function.

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients with Relapsed or Refractory Lymphomas and Solid Tumors

NCT06132503RecruitingPhase 1
Lantern Pharma Inc.
Posted 1/3/2023

IGC Pharma Unveils AI-Powered Alzheimer's Platforms at AAIC 2025

AIDrug Discovery
  • IGC Pharma will present three scientific posters at the 2025 Alzheimer's Association International Conference showcasing proprietary AI platforms for drug discovery and early disease detection.
  • The company's MINT-AD platform uses large language models to predict cognitive decline scores using only socioeconomic data, eliminating the need for brain scans or blood biomarkers.
  • IGC's hybrid AI-powered screening pipeline rapidly identifies interactions between proprietary molecules and Alzheimer's targets including GLP-1 and CB1 receptors.
  • The innovations aim to expand access to earlier diagnosis and accelerate therapeutic discovery, particularly in low-resource settings.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.